1. Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery Disease Undergoing Stress Myocardial Perfusion Single Photon Emission Computed Tomography
by Rory Hachamovitch, Sean W. Hayes, John D. Friedman, Ishac Cohen, and Daniel S. Berman
Circulation
Volume 107(23):
June 17, 2003
Copyright © American Heart Association, Inc. All rights reserved.

2. Figure 1. Unadjusted Kaplan-Meier survival in patients undergoing revascularization vs medical therapy (Medical Rx).
Figure 1. Unadjusted Kaplan-Meier survival in patients undergoing revascularization vs medical therapy (Medical Rx).
Rory Hachamovitch et al. Circulation. 2003;107:
Copyright © American Heart Association, Inc. All rights reserved.

3. Figure 2. Observed cardiac death rates over the follow-up period in patients undergoing revascularization (Revasc) vs medical therapy (Medical Rx) as a function of the amount of inducible ischemia.
Figure 2. Observed cardiac death rates over the follow-up period in patients undergoing revascularization (Revasc) vs medical therapy (Medical Rx) as a function of the amount of inducible ischemia. Increase in cardiac death frequency as a function of inducible ischemia, P<
Rory Hachamovitch et al. Circulation. 2003;107:
Copyright © American Heart Association, Inc. All rights reserved.

4. Figure 3. Likelihood of referral to revascularization as a function of % myocardium ischemic based on logistic regression analysis.
Figure 3. Likelihood of referral to revascularization as a function of % myocardium ischemic based on logistic regression analysis. TAP indicates typical angina; Atyp, atypical angina pectoris; and Asx, asymptomatic.
Rory Hachamovitch et al. Circulation. 2003;107:
Copyright © American Heart Association, Inc. All rights reserved.

5. Figure 4. Log hazard ratio for revascularization (Revasc) vs medical therapy (Medical Rx) as a function of % myocardium ischemic based on final Cox proportional hazards model.
Figure 4. Log hazard ratio for revascularization (Revasc) vs medical therapy (Medical Rx) as a function of % myocardium ischemic based on final Cox proportional hazards model. Model, P<0.0001; interaction, P=
Rory Hachamovitch et al. Circulation. 2003;107:
Copyright © American Heart Association, Inc. All rights reserved.